Iron treatment and the TREAT trial

NDT Plus

Volumn 4, Issue SUPPL. 1, 2011, Pages

  Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

anaemia; CKD; ESA; guidelines; iron therapy; TREAT trial

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; TRANSFERRIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; HYPERTENSION; IRON DEFICIENCY; IRON THERAPY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTOSIS; THROMBOSIS;

EID: 79958011614     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfr041     Document Type: Article

References (11)

1. Locatelli F, Aljama P, Bárány P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. European Best Practice Guidelines Working Group. Nephrol Dial Transplant 2004; 19: ii1-ii47
2. KDOQI. Clinical Practice Guidelines and Clinical practice recommendations for anemia in chronic kidney disease: 2007 update of haemoglobin target. Am J Kidney Dis 2007; 50: 471-530
3. De Nicola L, Conte G, Chiodini P et al. Stability of target hemoglobin levels during the first year of epoetin treatment in patients with chronic kidney disease. Clin J Am Soc Nephrol 2007092: 938-946
4. Pfeffer MA, Burdmann EA, Chen CYet al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
5. Locatelli F, Covic A, Eckardt KU et al. ERA-EDTA ERBP Advisory Board.Nephrol Dial Transplant. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-354
6. Locatelli F, Aljama P, Canaud B et al. On behalf of the Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrol Dial Transplant 2010; 25: 2846-2850
7. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590 (Pubitemid 28385655)
8. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med 2006; 335: 2085-2098 (Pubitemid 44749317)
9. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
10. Locatelli F, Del Vecchio L, Casartelli D. Darbepoetin alfa and chronic kidney disease. N Engl J Med 2010; 362: 654-655
11. Locatelli F, Del Vecchio L. Debate: CON Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol 2010; 31: 557-560